ORIC PHARMACEUTICALS

ORIC Pharmaceuticals Announces Clinical Development Collaboration with Pfizer for ORIC-533 in Multiple Myeloma and Concurrent $25 Million Equity Investment by Pfizer

21 Dec 2022 16:48:37 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Presents Preclinical Data Demonstrating ORIC-533 as a Potential Best-in-Class CD73 Inhibitor at the 64th American Society of Hematology (ASH) Annual Meeting

13 Dec 2022 07:00:01 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals to Present at the Jefferies London Healthcare Conference

08 Nov 2022 15:10:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Update

07 Nov 2022 15:05:01 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals to Present Preclinical Data on CD73 Inhibitor Program in Multiple Myeloma at the 64th American Society of Hematology (ASH) Annual Meeting

03 Nov 2022 08:00:01 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

07 Oct 2022 15:30:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

01 Sep 2022 15:15:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Update

11 Aug 2022 15:05:01 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals to Present at the Jefferies Healthcare Conference

02 Jun 2022 15:10:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

17 May 2022 15:10:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Update

09 May 2022 15:05:03 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Presents Promising Preclinical Data on Three Programs at the 2022 American Association for Cancer Research (AACR) Annual Meeting

12 Apr 2022 15:05:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Update

21 Mar 2022 15:00:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals to Host Fourth Quarter and Full Year 2021 Financial Results and Operational Update Conference Call

17 Mar 2022 15:30:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Announces Multiple Presentations at the 2022 American Association for Cancer Research (AACR) Annual Meeting

08 Mar 2022 15:30:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals to Participate in the Guggenheim 2022 Oncology Conference

02 Feb 2022 15:30:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Announces Regulatory Clearance of Clinical Trial Application for ORIC-114 in Advanced Solid Tumors with EGFR or HER2 Exon 20 Alterations or HER2 Amplifications

25 Jan 2022 07:30:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming Milestones

10 Jan 2022 07:00:10 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference

04 Jan 2022 15:30:00 By Nasdaq GlobeNewswire

ORIC Pharmaceuticals Presents Data Supporting the Therapeutic Potential of ORIC-533 in Multiple Myeloma at the American Society of Hematology (ASH) Annual Meeting

13 Dec 2021 15:15:00 By Nasdaq GlobeNewswire